All Oncology News

Jessica Jiyeong Lin, MD, discusses rare oncogenic drivers and elaborates on the updated efficacy analyses that were presented at the 2019 ASCO Annual Meeting.

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

A biologics license application has been submitted to the FDA for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Lecia V. Sequist, MD, MPH, highlights recent developments in NSCLC treatment and shared key questions that still need to be addressed.

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Alice T. Shaw, MD, PhD, provides an overlay of current treatment strategies in ALK-positive NSCLC and highlights research on the horizon.

Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.

Niraparib as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.

Justin F. Gainor, MD, highlights the evolving paradigm for the use of immunotherapy in the treatment of patients with unresectable locally advanced non–small cell lung cancer.

A supplemental biologics license application has been submitted to the FDA for a new subcutaneous formulation of daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Christopher Sweeney, MBBS, discusses the results of the ENZAMET trial and the next steps for researching the efficacy of enzalutamide in the treatment of patients with metastatic hormone-sensitive prostate cancer.

The FDA has granted an Orphan Drug Designation to durvalumab for the treatment of patients with small cell lung cancer, according to AstraZeneca, the developer of the PD-L1 inhibitor.

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Anna F. Farago, MD, PhD, discusses recent advances in the field of small cell lung cancer.

The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.

Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.

Inga T. Lennes, MD, MBA, MPH, discusses the recommended screening protocol for patients at risk for lung cancer, maintaining patients post-screening, and how physicians can best assist this patient population.

Ariela Noy, MD, discusses a phase II trial of devimistat in Burkitt lymphoma and other lymphomas, and describes the unique mechanism of action of the agent.

The FDA has granted a fast track designation to CLR 131 for use as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

New findings may lead to novel immunotherapies against third-deadliest cancer.

Mounzer E. Agha, MD, discusses the approaches that are leading to prolonged survival in patients with relapsed/refractory multiple myeloma.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.

Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.

The FDA has accepted an application for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma.

The oral modified dysfunctional tyrosine SM-88 demonstrated a median overall survival of 6.4 months in patients with advanced pancreatic cancer.

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Rafic Farah, MD, provides an in-depth look at the trials that now define standards of care among patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Annie Im, MD, discusses the importance of minimal residual disease in acute lymphoblastic leukemia, the role of transplant, and novel treatment approaches under investigation.

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.